Integrated (DEB transmission and economic combined) (n = 12) [9, 18–20, 25, 51, 54, 59, 61, 62, 64, 65]Dynamic transmission only (n = 70) c,dDEB (n = 45) [10, 14, 22, 26, 33–36, 38–40, 43, 47, 49, 52, 53, 55–58, 60, 68, 69, 73, 74, 77, 97, 147–157, 160, 162–166, 171] cSC (n = 15) [27, 46, 70, 71, 75, 76, 97–100, 147, 158, 161, 167–169]IB (n = 10) [24, 41, 129, 132–135, 155, 159, 170]dDES,DEB (n = 3) [4, 50, 81]Economic/cost analysis only (n = 15) [11, 12, 21, 23, 66, 78, 146, 172–179]Statistical analyses (by 3 GPEI-supported modeling groups only) (n = 38)Risk assessment (n = 19) [44, 93, 101, 102, 109–113, 116, 117, 130, 131, 136, 140–143, 145]Vaccine effectiveness (n = 17) [82–84, 87–92, 103–108, 114, 115]Mucosal immunity (n = 2) [85, 86]Reviews (by 3 GPEI-supported modeling groups only) (n = 14)Transmission model inputs (n = 11) [13, 29, 30, 32, 94, 96, 126–128, 138, 139]Risk model inputs (n = 3) [67, 72, 125]Discussions (by 3 GPEI-supported modeling groups only) (n = 26)Policy options (n = 5) [8, 28, 31, 37, 80]Perspectives (n = 13) [1-3, 15–17, 45, 63, 95, 122, 124, 137, 144]Commentaries (n = 8) [42, 48, 79, 118–121, 123]